Dataset Information

Alterations in fecal metagenomics and serum metabolomics indicate management strategies for patients with Budd-Chiari syndrome

ABSTRACT:

OBJECTIVES: We investigated the effects of gut microbiota and serum metabolic levels on the patients with Budd-Chiari syndrome (B-CS), and their guidance for clinical management strategies.

DESIGN: 214 B-CS subjects including untreated case (n=93) and treated case (n=121), were enrolled in this study. Gut microbiota and serum metabolome were analyzed using shotgun metagenomics and liquid chromatography mass spectrometry (LC-MS). 41 controls were included.

RESULTS: The gut microbiota in B-CS patients showed greater abundance of Campylobacter and lower Saccharomyces, Deinococcus and Thiomonas (P < 0.05). 13 differential metabolites such as taurocholate and (R)−3−Hydroxybutyric acid were identified in B-CS patients. The random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC =58.48%, 95% CI: 38.46% – 78.5%). The results of association analysis showed that Campylobacter concisus and taurocholate were significantly positively correlated in B-CS patients with clinical manifestations (P < 0.05). Moreover, Actinobacteria was significantly increased in untreated B-CS patients vs. treated B-CS patients (P < 0.05). Campylobacter and Veillonella were significantly increased in treated B-CS patients vs. health controls (P < 0.05). In addition, Fewer discrepant microbes were found between treated and untreated groups for the patients without clinical manifestation.

CONCLUSIONS: We identified major alterations in the gut microbiota and serum metabolome of B-CS patients. Alterations in fecal metagenomics and serum metabolomics guided management strategies for the patients with Budd-Chiari syndrome.

INSTRUMENT(S): Liquid Chromatography MS -

SUBMITTER: Yuling Sun

PROVIDER: MTBLS2319 | MetaboLights | 2021-10-20

REPOSITORIES: MetaboLights

ACCESS DATA

Similar Datasets

Project description:PURPOSE: Olfactory dysfunction (OD) is a debilitating symptom frequently reported by patients with chronic rhinosinusitis (CRS) and it is associated with a dysregulated sinonasal inflammation. However, little information is available about the effect of the inflammation-related nasal microbiota and related metabolites on the olfactory function in these patients. Therefore, the current study aimed to investigate the nasal microbiota-metabolites-immune interactions and their role in the pathogenesis of OD in CRS patients.METHODS: 23 and 19 CRS patients with and without OD (NOD), respectively, were enrolled in the present study. The 'Sniffin' Sticks' was used to measure the olfactory function, while the metagenomic shotgun sequencing and the untargeted metabolomic profiling were performed to assess the differences in terms of the nasal microbiome and metabolome between the two groups. The levels of nasal mucus inflammatory mediators were investigated by a multiplex flow Cytometric Bead Array (CBA).RESULTS: A decreased diversity in the nasal microbiome from the OD group compared to the NOD group was evidenced. The metagenomic analysis revealed a significant enrichment of Acinetobacter johnsonii in the OD group, while Mycoplasma arginini, Aeromonas dhakensis and Salmonella enterica were significantly less represented (LDA value > 3, p < 0.05). The nasal metabolome profiles were significantly different between the OD and NOD groups (P < 0.05). The purine metabolism was the most significantly enriched metabolic subpathway in OD patients compared with NOD patients (P < 0.001). The expressions of IL-5, IL-8, MIP-1alpha, MCP-1 and TNF were statistically and significantly increased in the OD group (P < 0.05). All these data, including the dysregulation of the nasal microbiota, differential metabolites and elevated inflammatory mediators in OD patients demonstrated a clear interaction relationship.CONCLUSIONS: The disturbed nasal microbiota-metabolite-immune interaction networks may be implicated in the pathogenesis of OD in CRS patients and the underlying pathophysiological mechanisms need to be further investigated in future studies.

Dataset Information

Alterations in fecal metagenomics and serum metabolomics indicate management strategies for patients with Budd-Chiari syndrome

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure